| scholarly article | Q13442814 |
| P50 | author | Justin B Kinney | Q57517713 |
| P2093 | author name string | Christopher R Vakoc | |
| Junwei Shi | |||
| Eric Wang | |||
| Zihua Wang | |||
| Joseph P Milazzo | |||
| P2860 | cites work | Genome engineering using the CRISPR-Cas9 system | Q22122027 |
| RNA-guided human genome engineering via Cas9 | Q24598394 | ||
| Multiplex genome engineering using CRISPR/Cas systems | Q24609428 | ||
| A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity | Q24669850 | ||
| Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Q27674674 | ||
| The mechanisms behind the therapeutic activity of BET bromodomain inhibition | Q28241504 | ||
| Development and applications of CRISPR-Cas9 for genome engineering | Q28241526 | ||
| Reversible suppression of an essential gene in adult mice using transgenic RNA interference | Q28512942 | ||
| Plat-E: an efficient and stable system for transient packaging of retroviruses | Q29614830 | ||
| DNA targeting specificity of RNA-guided Cas9 nucleases | Q29615793 | ||
| Genome-scale CRISPR-Cas9 knockout screening in human cells | Q29616044 | ||
| Targeting MYC dependence in cancer by inhibiting BET bromodomains | Q29617196 | ||
| RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia | Q29617201 | ||
| Genetic screens in human cells using the CRISPR-Cas9 system | Q29617411 | ||
| Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. | Q33716402 | ||
| The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. | Q33915185 | ||
| Saturation editing of genomic regions by multiplex homology-directed repair | Q34143368 | ||
| Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation | Q34388531 | ||
| Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. | Q34436638 | ||
| Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia | Q34876825 | ||
| Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library | Q35096218 | ||
| High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells | Q35143589 | ||
| Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi | Q36088050 | ||
| Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia | Q36673042 | ||
| The methyltransferase G9a regulates HoxA9-dependent transcription in AML. | Q37608196 | ||
| Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer | Q41942526 | ||
| The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells | Q45375299 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 6 | |
| P921 | main subject | drug screening | Q10505555 |
| CRISPR | Q412563 | ||
| Cas9 | Q16965677 | ||
| CRISPR-Cas method | Q17310682 | ||
| P304 | page(s) | 661-667 | |
| P577 | publication date | 2015-05-11 | |
| P1433 | published in | Nature Biotechnology | Q1893837 |
| P1476 | title | Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains | |
| P478 | volume | 33 |
| Q35950415 | 2C-Cas9: a versatile tool for clonal analysis of gene function |
| Q34543038 | A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. |
| Q41122658 | A CRISPR Resource for Individual, Combinatorial, or Multiplexed Gene Knockout |
| Q36408534 | A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. |
| Q47644126 | A High-Resolution Genome-Wide CRISPR/Cas9 Viability Screen Reveals Structural Features and Contextual Diversity of the Human Cell-Essential Proteome. |
| Q38818753 | A Medium-Throughput Single Cell CRISPR-Cas9 Assay to Assess Gene Essentiality |
| Q50422144 | A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response |
| Q89967404 | A Pilot Study of All-Computational Drug Design Protocol-From Structure Prediction to Interaction Analysis |
| Q92378292 | A Practical Guide to Genome Editing Using Targeted Nuclease Technologies |
| Q90926961 | A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality |
| Q48544889 | A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia. |
| Q64905283 | A Transcription Factor Addiction in Leukemia Imposed by the MLL Promoter Sequence. |
| Q90164309 | A benchmark of algorithms for the analysis of pooled CRISPR screens |
| Q36942027 | A genome editing primer for the hematologist |
| Q26781135 | A new age in functional genomics using CRISPR/Cas9 in arrayed library screening |
| Q38715347 | A stable but reversible integrated surrogate reporter for assaying CRISPR/Cas9-stimulated homology-directed repair. |
| Q47561032 | Acute multi-sgRNA knockdown of KEOPS complex genes reproduces the microcephaly phenotype of the stable knockout zebrafish model. |
| Q38725573 | Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. |
| Q92163342 | Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets |
| Q47281660 | Am I ready for CRISPR? A user's guide to genetic screens |
| Q78177253 | Application of CRISPR genetic screens to investigate neurological diseases. |
| Q55309854 | Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer. |
| Q38947491 | Applications of CRISPR Genome Engineering in Cell Biology |
| Q38708498 | Applications of CRISPR genome editing technology in drug target identification and validation |
| Q34539796 | Applications of CRISPR technologies in research and beyond |
| Q92697422 | Attenuating the emergence of anti-fungal drug resistance by harnessing synthetic lethal interactions in a model organism |
| Q101166870 | BAHCC1 binds H3K27me3 via a conserved BAH module to mediate gene silencing and oncogenesis |
| Q38779981 | BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. |
| Q33725257 | Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains |
| Q90131783 | Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death |
| Q55217604 | CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation. |
| Q38645581 | CRISPR Editing in Biological and Biomedical Investigation. |
| Q30742370 | CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs |
| Q28075898 | CRISPR guide RNA design for research applications |
| Q35969850 | CRISPR library designer (CLD): software for multispecies design of single guide RNA libraries |
| Q55383943 | CRISPR therapeutic tools for complex genetic disorders and cancer (Review). |
| Q64074957 | CRISPR to fix bad blood: a new tool in basic and clinical hematology |
| Q39014648 | CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes |
| Q102063582 | CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries |
| Q38670939 | CRISPR-Cas9 for medical genetic screens: applications and future perspectives |
| Q38822073 | CRISPR-Cas9 technology and its application in haematological disorders |
| Q49477344 | CRISPR-Cas9: a promising genetic engineering approach in cancer research |
| Q91142488 | CRISPR-Cas: a tool for cancer research and therapeutics |
| Q39611364 | CRISPR-DO for genome-wide CRISPR design and optimization |
| Q40066344 | CRISPR-FOCUS: A web server for designing focused CRISPR screening experiments. |
| Q91620620 | CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment |
| Q93139098 | CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML |
| Q64081762 | CRISPR/Cas9 - An evolving biological tool kit for cancer biology and oncology |
| Q64386978 | CRISPR/Cas9 as a tool to dissect cancer mutations |
| Q38825322 | CRISPR/Cas9 genome editing in human pluripotent stem cells: Harnessing human genetics in a dish |
| Q42108657 | CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials |
| Q36196813 | CRISPR/Cas9-The ultimate weapon to battle infectious diseases? |
| Q52430362 | CRISPR/Cas9-mediated target validation of the splicing inhibitor Pladienolide B. |
| Q33772342 | CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery |
| Q38614582 | CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer |
| Q57810098 | CRISPRO: identification of functional protein coding sequences based on genome editing dense mutagenesis |
| Q46190066 | CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine |
| Q33573686 | CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells |
| Q33922903 | CRISPulator: a discrete simulation tool for pooled genetic screens |
| Q97643334 | Chemical strategies to overcome resistance against targeted anticancer therapeutics |
| Q42687340 | Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2. |
| Q38711552 | Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions. |
| Q38734451 | Combine and conquer: challenges for targeted therapy combinations in early phase trials. |
| Q38626061 | Combining CRISPR/Cas9 and rAAV Templates for Efficient Gene Editing |
| Q64988443 | Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline. |
| Q91658745 | Conceptual Evolution of Cell Signaling |
| Q39051110 | Cornerstones of CRISPR-Cas in drug discovery and therapy |
| Q46776672 | Correcting CRISPR for copy number |
| Q38682882 | Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery |
| Q36258853 | Creation of Novel Protein Variants with CRISPR/Cas9-Mediated Mutagenesis: Turning a Screening By-Product into a Discovery Tool |
| Q102134513 | Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy |
| Q64057805 | Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia |
| Q26751061 | Customizing the genome as therapy for the β-hemoglobinopathies |
| Q39047646 | DNMT3A in Leukemia. |
| Q90495495 | De novo identification of essential protein domains from CRISPR-Cas9 tiling-sgRNA knockout screens |
| Q99579418 | Designing custom CRISPR libraries for hypothesis-driven drug target discovery |
| Q90135125 | Development of targeted protein degradation therapeutics |
| Q38669948 | Developmental history and application of CRISPR in human disease |
| Q96610114 | Discovering and validating cancer genetic dependencies: approaches and pitfalls |
| Q48974484 | Discovery of rice essential genes by characterizing a CRISPR-edited mutation of closely related rice MAP kinase genes |
| Q38855791 | Distinct functions of histone H3, lysine 4 methyltransferases in normal and malignant hematopoiesis |
| Q37683769 | Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. |
| Q63433323 | Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells |
| Q58609423 | DrugThatGene: integrative analysis to streamline the identification of druggable genes, pathways, and protein complexes from CRISPR screens |
| Q38641649 | Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. |
| Q36169265 | EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. |
| Q57470764 | Efficient CRISPR/Cas9-Mediated Mutagenesis in Primary Murine T Lymphocytes |
| Q90266900 | Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia |
| Q26782747 | Enabling functional genomics with genome engineering |
| Q38696102 | Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis |
| Q50028355 | Enhancer dysfunction in leukemia. |
| Q37424191 | Erythropoiesis provides a BRD's eye view of BET protein function |
| Q92159013 | Essential genes shape cancer genomes through linear limitation of homozygous deletions |
| Q50302255 | Exploiting genetic variation to uncover rules of transcription factor binding and chromatin accessibility. |
| Q36956610 | Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. |
| Q33879061 | Flexible CRISPR library construction using parallel oligonucleotide retrieval. |
| Q48747209 | Functional Genomic Characterization of Cancer Genomes |
| Q52673134 | Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands |
| Q39688289 | Functional interdependence of BRD4 and DOT1L in MLL leukemia |
| Q36306820 | Functional interrogation of non-coding DNA through CRISPR genome editing |
| Q47734473 | GUIDES: sgRNA design for loss-of-function screens. |
| Q88984520 | Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome |
| Q57170220 | Gene editing in the context of an increasingly complex genome |
| Q90019632 | Generating Single Cell-Derived Knockout Clones in Mammalian Cells with CRISPR/Cas9 |
| Q50915851 | Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML. |
| Q90496005 | Genetic modification of primary human B cells to model high-grade lymphoma |
| Q104745214 | Genetic screening for single-cell variability modulators driving therapy resistance |
| Q84957547 | Genome-Wide CRISPR Screen Identifies Host Factors Required by Infection |
| Q36221012 | Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. |
| Q36040827 | Genome-scale CRISPR pooled screens |
| Q34553929 | Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening |
| Q33654299 | Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens |
| Q52686206 | Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS. |
| Q27320024 | Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells |
| Q91607212 | Genome-wide CRISPR-Cas9 screening in mammalian cells |
| Q42377775 | Genomic Amplifications Cause False Positives in CRISPR Screens |
| Q49647261 | Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes |
| Q90437192 | Global regulation of the histone mark H3K36me2 underlies epithelial plasticity and metastatic progression |
| Q36306488 | Guide Picker is a comprehensive design tool for visualizing and selecting guides for CRISPR experiments. |
| Q91892521 | HBO1 is required for the maintenance of leukaemia stem cells |
| Q57072375 | HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis |
| Q36482298 | High-Content Analysis of CRISPR-Cas9 Gene-Edited Human Embryonic Stem Cells |
| Q47594697 | High-Throughput Approaches to Pinpoint Function within the Noncoding Genome |
| Q97528957 | High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening |
| Q57753797 | High-throughput creation and functional profiling of DNA sequence variant libraries using CRISPR-Cas9 in yeast |
| Q36163361 | High-throughput strategies for the discovery and engineering of enzymes for biocatalysis |
| Q64928671 | Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. |
| Q91560440 | Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma |
| Q96128046 | Identification of a potent and selective covalent Pin1 inhibitor |
| Q38597446 | Identification of drug candidates and repurposing opportunities through compound-target interaction networks |
| Q28596034 | Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening |
| Q91753638 | Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia |
| Q88989638 | Improved design and analysis of CRISPR knockout screens |
| Q90380788 | Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis |
| Q92648102 | Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9 |
| Q39039446 | Integrated Approaches to Drug Discovery for Oxidative Stress-Related Retinal Diseases. |
| Q52431517 | Integrated design, execution, and analysis of arrayed and pooled CRISPR genome-editing experiments. |
| Q64117207 | Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute |
| Q47635521 | Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action. |
| Q98237915 | KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements |
| Q52430746 | LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia. |
| Q49913945 | LSD1 inhibition exerts its anti-leukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. |
| Q40975838 | Leapfrogging: primordial germ cell transplantation permits recovery of CRISPR/Cas9-induced mutations in essential genes |
| Q41066571 | Lentiviral Fluorescent Genetic Barcoding for Multiplex Fate Tracking of Leukemic Cells |
| Q91062934 | Liposomal delivery of CRISPR/Cas9 |
| Q38691620 | Logic Modeling in Quantitative Systems Pharmacology |
| Q132042177 | MARK2/MARK3 Kinases Are Catalytic Codependencies of YAP/TAZ in Human Cancer |
| Q132048865 | MARK2/MARK3 kinases are catalytic co-dependencies of YAP/TAZ in human cancer |
| Q55279675 | MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. |
| Q48022971 | MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia |
| Q38747872 | Marked for death: targeting epigenetic changes in cancer |
| Q98952047 | Maximizing CRISPR/Cas9 phenotype penetrance applying predictive modeling of editing outcomes in Xenopus and zebrafish embryos |
| Q48569638 | Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation. |
| Q38598073 | Modeling Disease In Vivo With CRISPR/Cas9. |
| Q26741086 | Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling Networks |
| Q96230788 | Multilayered VBC score predicts sgRNAs that efficiently generate loss-of-function alleles |
| Q35920105 | Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM. |
| Q42631262 | Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6. |
| Q36395823 | NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler. |
| Q36232406 | Network analysis of gene essentiality in functional genomics experiments |
| Q47116263 | Nicotinic Acetylcholine Receptor Subtype Alpha-9 Mediates Triple-Negative Breast Cancers Based on a Spontaneous Pulmonary Metastasis Mouse Model |
| Q90068431 | Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials |
| Q41071025 | One-step generation of complete gene knockout mice and monkeys by CRISPR/Cas9-mediated gene editing with multiple sgRNAs |
| Q35896845 | Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. |
| Q38671390 | Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. |
| Q92017374 | PASTMUS: mapping functional elements at single amino acid resolution in human cells |
| Q93177502 | PAVOOC: designing CRISPR sgRNAs using 3D protein structures and functional domain annotations |
| Q43293647 | PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes |
| Q64967099 | POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. |
| Q61919912 | Pentose conversions support the tumorigenesis of pancreatic cancer distant metastases |
| Q38904862 | Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration. |
| Q52584570 | Pluripotency transcription factors and Tet1/2 maintain Brd4-independent stem cell identity. |
| Q91432412 | Pooled CRISPR Screens in Drosophila Cells |
| Q36065701 | Practical Considerations for Using Pooled Lentiviral CRISPR Libraries. |
| Q34480103 | Precision cancer mouse models through genome editing with CRISPR-Cas9. |
| Q39126189 | Precision genome editing in the CRISPR era. |
| Q64270649 | Preclinical rationale for entinostat in embryonal rhabdomyosarcoma |
| Q63649593 | Predicting the mutations generated by repair of Cas9-induced double-strand breaks |
| Q50010382 | Primordial Germ Cell Transplantation for CRISPR/Cas9-based Leapfrogging in Xenopus |
| Q37334404 | Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia. |
| Q47352505 | Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. |
| Q55314041 | Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery. |
| Q98623725 | Proteosomal degradation of NSD2 by BRCA1 promotes leukemia cell differentiation |
| Q64388008 | RAD52 and SLX4 act nonepistatically to ensure telomere stability during alternative telomere lengthening |
| Q55504424 | RIOK1 kinase activity is required for cell survival irrespective of MTAP status. |
| Q37661378 | Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization |
| Q36288331 | Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis. |
| Q93117329 | Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis |
| Q41734326 | Regulation of cancer epigenomes with a histone-binding synthetic transcription factor |
| Q26776435 | Resources for the design of CRISPR gene editing experiments |
| Q94482231 | Role of Meningioma 1 for maintaining the transformed state in MLL-rearranged acute myeloid leukemia: potential for therapeutic intervention? |
| Q64095498 | Roles of SETD2 in Leukemia-Transcription, DNA-Damage, and Beyond |
| Q38994704 | SET/MLL family proteins in hematopoiesis and leukemia. |
| Q91711100 | SETD2 in MLL-rearranged leukemia - a complex case |
| Q92578345 | SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines |
| Q60300790 | SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4 |
| Q28829718 | Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition |
| Q47831063 | Silencing of retrotransposons by SETDB1 inhibits the interferon response in acute myeloid leukemia. |
| Q42222276 | Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin |
| Q53684294 | Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9. |
| Q42222741 | Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex. |
| Q58594046 | Stem Cells, Genome Editing, and the Path to Translational Medicine |
| Q42645888 | Survival of pancreatic cancer cells lacking KRAS function. |
| Q34046778 | Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes |
| Q99565949 | Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library |
| Q92812671 | TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion |
| Q60054767 | TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma |
| Q47356354 | Target Discovery for Precision Medicine Using High-Throughput Genome Engineering |
| Q48105865 | Target validation: Switching domains |
| Q59800754 | Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma |
| Q59441078 | Targeted therapy for fusion-driven high-risk acute leukemia |
| Q41616680 | Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. |
| Q36347511 | Targeting Transcription Factors in Cancer |
| Q91865401 | Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia |
| Q64951709 | Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. |
| Q38707876 | Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs |
| Q37716654 | Targeting microRNAs: a new action mechanism of natural compounds. |
| Q47554878 | Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth. |
| Q26824997 | The CRISPR revolution and its impact on cancer research |
| Q64290214 | The E3 ligase adaptor molecule SPOP regulates fetal hemoglobin levels in adult erythroid cells |
| Q92579042 | The E3 ubiquitin ligase SPOP controls resolution of systemic inflammation by triggering MYD88 degradation |
| Q41330428 | The Essential Transcriptional Function of BRD4 in Acute Myeloid Leukemia |
| Q38896059 | The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer |
| Q45067620 | The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. |
| Q50420957 | The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma |
| Q38872633 | The applications of CRISPR screen in functional genomics. |
| Q38836751 | The big bang of genome editing technology: development and application of the CRISPR/Cas9 system in disease animal models |
| Q38743881 | The cancer epigenome: Concepts, challenges, and therapeutic opportunities |
| Q38929394 | The other side of the coin: Leveraging Epstein-Barr virus in research and therapy |
| Q28066254 | The potential for tumor suppressor gene therapy in head and neck cancer |
| Q38840267 | The present and future of genome editing in cancer research |
| Q91861384 | Towards quantitative and multiplexed in vivo functional cancer genomics |
| Q38714675 | Transcription control by the ENL YEATS domain in acute leukaemia |
| Q38831313 | Uncharted Waters: Zebrafish Cancer Models Navigate a Course for Oncogene Discovery |
| Q90689982 | Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants |
| Q64103126 | Unlocking HDR-mediated nucleotide editing by identifying high-efficiency target sites using machine learning |
| Q90099938 | VPS37A directs ESCRT recruitment for phagophore closure |
| Q90441183 | Validation of a Miniaturized Permeability Assay Compatible with CRISPR-Mediated Genome-Wide Screen |
| Q64054862 | Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells |
| Q91272163 | eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma |
| Q89980695 | gscreend: modelling asymmetric count ratios in CRISPR screens to decrease experiment size and improve phenotype detection |
Search more.